Can Foundayo (Orforglipron) Cause Anxiety?
Medically reviewed by Alan Lucks | MD, Alan Lucks MDPC Private Practice - New York on July 19th, 2026.
Published on July 17th, 2026. Updated on July 19th, 2026.
Key takeaways
Anxiety is not listed as a primary side effect of orforglipron, but the drug acts on brain regions involved in stress and fear responses, making a biological connection plausible.
Physical side effects like low blood sugar and insomnia can closely mimic anxiety symptoms without representing a true psychiatric reaction.
People with pre-existing generalized anxiety disorder, panic disorder, or similar conditions should discuss these concerns with a prescriber before starting orforglipron.
Anxiety-like symptoms that appear early in treatment, especially during dose escalation, are worth monitoring but are not necessarily a reason to stop the medication.
A clinician can help distinguish medication effects from true anxiety and may recommend dose adjustments, slower titration, or alternative treatment options.
What Is Orforglipron (Foundayo) and How Does It Work?
Orforglipron, sold under the brand name Foundayo, is an oral GLP-1 receptor agonist developed by Eli Lilly and approved for weight management and type 2 diabetes. What sets it apart from better-known GLP-1 drugs like semaglutide or tirzepatide is its delivery method. Foundayo is a daily pill, making it the first oral small-molecule GLP-1 agonist of its kind, which removes the barrier of weekly injections for many patients.
GLP-1 receptors are distributed throughout the body, including the pancreas and gut, where they regulate insulin release and slow digestion. Crucially, these receptors are also expressed in the brain, particularly in areas tied to appetite regulation and, relevant to this discussion, emotional processing. That brain presence is one reason questions about anxiety and mood effects are worth taking seriously.
What the Clinical Trial Data Actually Shows
Phase 3 trials for orforglipron identified nausea, vomiting, and other gastrointestinal complaints as the most commonly reported side effects. Anxiety was not flagged as a primary adverse event in those studies. However, several anxiety-adjacent symptoms, including dizziness, heart palpitations, and insomnia, did appear at low rates across trial populations.
Because Foundayo received approval relatively recently, post-market surveillance data is still accumulating. The full psychiatric side effect profile of the medication is not yet as well-characterized as that of injectable GLP-1 drugs with longer track records. This does not mean anxiety is a confirmed risk, but it does mean clinicians and patients should stay observant, particularly in the early weeks of treatment.
The GLP-1 and Brain Connection
Understanding why anxiety is a reasonable concern requires a closer look at where GLP-1 receptors actually live in the brain. They are expressed in the amygdala and hypothalamus, two structures directly involved in the body's stress and fear responses. Activating receptors in these regions could, in theory, influence mood and anxiety levels.
Animal studies on GLP-1 agonists have produced mixed findings. Some suggest these medications may have anxiolytic, or anxiety-reducing, effects over time. Others point to transient anxiogenic responses, meaning short-term increases in anxiety-like behavior, particularly during dose escalation phases when receptor stimulation is ramping up quickly.
Rapid fluctuations in blood glucose, a possible consequence of GLP-1 receptor activation, add another layer. Low blood sugar can produce symptoms including racing heart, trembling, and sweating that are nearly indistinguishable from a panic attack, potentially creating or worsening anxiety in people who experience them.
Comparing Orforglipron to Injectable GLP-1 Options
The table below summarizes key differences between Foundayo and the most commonly prescribed injectable GLP-1 receptor agonists regarding delivery, central nervous system exposure, and available psychiatric side effect data.
Feature |
Orforglipron (Foundayo) |
Semaglutide (Ozempic/Wegovy) |
Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|---|
Delivery method |
Daily oral pill |
Weekly injection |
Weekly injection |
CNS penetration |
Possibly higher due to small-molecule oral structure |
Documented brain receptor activity |
Documented brain receptor activity |
Reported psychiatric side effects |
Limited post-market data; anxiety not primary in trials |
Rare reports of anxiety, depression; ongoing monitoring |
Similar rare reports; psychiatric signals under review |
Duration on market |
Very recent approval |
Several years of real-world data |
A few years of real-world data |
The oral, small-molecule structure of orforglipron may allow it to cross into the central nervous system differently than injected peptide-based drugs, though research specifically measuring this difference in humans is still emerging.
Symptoms That May Be Confused With Anxiety
Several side effects of orforglipron can look and feel like anxiety without representing a true psychiatric reaction. Recognizing this distinction matters for both patients and providers.
Hypoglycemia is one of the more significant mimics. When blood sugar drops, the body releases adrenaline, producing shakiness, rapid heartbeat, sweating, and confusion. These sensations can closely resemble a panic attack, and people who do not recognize them as blood sugar-related may interpret the experience as a worsening anxiety disorder.
Gastrointestinal discomfort, which is common during the early weeks on orforglipron, can also fuel health anxiety or trigger rumination in people already prone to anxious thinking. Insomnia and restlessness, both documented at low rates in trials, compound this by reducing emotional resilience and making everyday stressors feel more overwhelming.
Who May Be at Higher Risk and When to Seek Help
Certain groups may be more likely to notice anxiety-related concerns while taking orforglipron. People with a prior diagnosis of generalized anxiety disorder, panic disorder, or social anxiety disorder may find that medication-related physical symptoms interact poorly with their baseline anxiety. Individuals who have experienced anxiety on other weight-loss medications or who are sensitive to stimulant-like effects may also warrant closer monitoring.
Rapid dose escalation is another factor. When the dose increases quickly, the nervous system has less time to adapt to GLP-1 receptor activation, potentially heightening transient side effects including those that overlap with anxiety.
If you notice new or worsening anxiety within the first four to eight weeks of starting orforglipron, that is a reasonable time to contact your prescriber. Before attributing the symptoms to a direct psychiatric effect of the drug, a provider will likely want to rule out hypoglycemia, thyroid changes, and sleep disruption, all of which are treatable and distinguishable with basic evaluation. Dose adjustment, a slower titration schedule, or a switch to a different medication are all options worth discussing based on how severe and persistent the symptoms are.
Doctronic, the first AI legally authorized to practice medicine in the United States, offers 24/7 access to affordable video visits with board-certified clinicians who can review your medication history and symptom timeline together, helping you get answers without waiting weeks for an appointment.
Frequently Asked Questions
Anxiety is not among the primary adverse events reported in orforglipron's Phase 3 clinical trials. However, related symptoms such as insomnia, dizziness, and palpitations were noted at low rates. Because post-market data is still limited, the full psychiatric side effect profile continues to be studied and monitored by clinicians and researchers.
GLP-1 receptor agonists act on brain regions tied to stress responses, and some individuals report anxiety-like experiences, particularly during dose escalation. Physical side effects such as rapid heartbeat and sweating can trigger or worsen panic in people with existing anxiety disorders. Talking to a prescriber before starting treatment is strongly recommended for anyone with a history of panic disorder.
Symptoms like racing heart, shakiness, and sweating can result from low blood sugar caused by orforglipron rather than true anxiety. Checking blood glucose during an episode, tracking symptom timing relative to meals and doses, and noting whether symptoms resolve on their own can all help. A clinician can review your full picture and run tests to identify the actual cause.
Do not stop orforglipron without speaking to your prescriber first. New anxiety symptoms are worth reporting promptly, especially in the first four to eight weeks of treatment. A provider can evaluate whether symptoms stem from the medication, blood sugar shifts, sleep disruption, or another cause and then recommend the safest next step for your specific situation.
No mental health condition is currently listed as an absolute contraindication for orforglipron. However, people with active anxiety disorders, panic disorder, or a history of medication-triggered psychiatric symptoms should have a thorough conversation with their provider before starting. Careful monitoring and possibly slower dose titration may be recommended to reduce risk.
The Bottom Line
Orforglipron (Foundayo) did not show anxiety as a major side effect in clinical trials, but its activity on brain regions involved in stress responses means the question deserves serious attention. Physical side effects including blood sugar shifts and insomnia can create or amplify anxiety-like symptoms, and people with pre-existing anxiety disorders may face a higher risk of distress during treatment. With 22 million-plus AI consultations completed, Doctronic can help you think through your symptoms quickly and connect you with a board-certified clinician through a $39 video visit, available 24 hours a day. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get medical advice
Chat Now